Rosen Law says it filed securities class action against PROCEPT BioRobotics
Rosen Law Firm says investors who bought PROCEPT BioRobotics common stock during the stated class period may seek to lead the case, with a Sept. 22, 2026 motion deadline in the notice.
Rosen Law Firm says investors who bought PROCEPT BioRobotics common stock during the stated class period may seek to lead the case, with a Sept. 22, 2026 motion deadline in the notice.
Rosen Law Firm says it has filed a securities class action against PROCEPT BioRobotics Corporation, according to a PR Newswire notice dated Aug. 3, 2026. The notice says the case covers investors who bought PROCEPT common stock between Feb. 28, 2024 and Feb. 25, 2026, inclusive.
The notice says investors who purchased during that period may be entitled to compensation under a contingency fee arrangement, with no out-of-pocket fees or costs. It also says anyone seeking to serve as lead plaintiff must move the court by Sept. 22, 2026.
According to the notice, the proposed complaint alleges PROCEPT used an extensive discount program to encourage bulk orders beyond procedure demand. The notice says that allegedly inflated reported U.S. handpiece unit sales and revenues, created excess field inventory, and left the company exposed to undisclosed operational and financial harm.
The notice further alleges the company could not achieve stated 2025 handpiece sales and revenue guidance and that investors suffered damages when the truth emerged. The notice says no class has been certified.
PROCEPT BioRobotics trades on Nasdaq under the ticker PRCT, according to the notice. It says investors may remain absent class members or choose their own counsel.
Rosen’s notice also says a lead plaintiff is a representative party that acts on behalf of other class members in directing the litigation. The notice provides a join link, toll-free phone number and email address for people seeking information.
The notice’s lead-plaintiff deadline is Sept. 22, 2026.
Sources
Editorial note: This article was prepared with AI assistance and includes source attribution for reader review.
View the Web StoryA visual, tap-through version of this reportThis is the AMP version of the article. Read the full article on Atlas Watchline.